RM Primary Logo - Humble.png
Revolution Medicines Completes Acquisition of EQRx
09 nov. 2023 09h10 HE | Revolution Medicines, Inc.
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning,...
RM Primary Logo - Humble.png
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
08 nov. 2023 11h30 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for...
RM Primary Logo - Humble.png
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
06 nov. 2023 16h05 HE | Revolution Medicines, Inc.
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to...
RM Primary Logo - Humble.png
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
01 nov. 2023 07h00 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
ScipherTM.png
UPDATE - Scipher Medicine Welcomes Sam Davis as General Counsel
24 sept. 2021 12h00 HE | Scipher Medicine Corporation
WALTHAM, Mass., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of Sam A....
ScipherTM.png
Scipher Medicine Welcomes Sam Davis as General Counsel
24 sept. 2021 09h00 HE | Scipher Medicine Corporation
WALTHAM, Mass., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapies, today announced the appointment of Sam A....